Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 11/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2832270 | 0.92 | NR1I2 (0.66) | LSS | |
| SCHEMBL1009221 | 0.90 | LSS (0.78) | LSS | |
| SCHEMBL188732 | 0.90 | LSS (0.78) | LSS | |
| SCHEMBL1142772 | 0.90 | LSS (0.78) | LSS | |
| SCHEMBL1401906 | 0.90 | LSS (0.78) | LSS | |
| SCHEMBL2836832 | 0.88 | NR1I2 (0.69) | LSS | |
| SCHEMBL29711771 | 0.85 | LSS (0.83) | LSS | |
| SCHEMBL29711785 | 0.85 | LSS (0.83) | LSS | |
| SCHEMBL5201689 | 0.83 | LSS (0.56) | LSS | |
| SCHEMBL2896117 | 0.81 | KMT2A (0.73) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866323-B1 | GLUCURONIDATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-1848424-B1 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2808015-A1 | Compositions comprising nebivolol | MYLAN LABORATORIES, INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20110065783-A1 | HYDROXYLATED NEBIVOLOL METABOLITES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-17 | — | — | US | disclosed |
| US-7838552-B2 | Compositions comprising nebivolol | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-23 | — | — | US | disclosed |
| EP-2174658-A1 | Compositions comprising nebivolol | MYLAN LABORATORIES, INC (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20080161296-A1 | Compositions comprising nebivolol | DEY, INC. (F/K/A DEY LABORATORIES, INC.) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161296-A1 | Compositions comprising nebivolol | ADRB1, ADRB3, ADRB2 | LSS 498/4885 |
| US-20110065783-A1 | HYDROXYLATED NEBIVOLOL METABOLITES | EDNRB, EDNRA, ADRB1 | LSS 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.